Biotech | October 26, 2021
Biological E to receive US $ 50 million to boost Covid-19 vaccine capacity
Support from DFC will help produce one billion vaccine doses by the end of 2022
Support from DFC will help produce one billion vaccine doses by the end of 2022
The list of kids with co-morbidities eligible for vaccination would be announced by the government
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older
It recommends using the vaccine to prevent the spread of the disease
This is the first time in South Asia an indigenously made drone was used to transport Covid-19 vaccines
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
It is a recombinant nanoparticle protein-based vaccine
The pivotal Phase 3 trial achieved all primary endpoints, demonstrating non-inferiority to a leading U.S.-licensed quadrivalent influenza vaccine
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
Subscribe To Our Newsletter & Stay Updated
